Lineage Cell Therapeutics (LCTX) Payables (2016 - 2025)
Historic Payables for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $4.6 million.
- Lineage Cell Therapeutics' Payables rose 163.06% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 163.06%. This contributed to the annual value of $5.4 million for FY2024, which is 1328.55% down from last year.
- As of Q3 2025, Lineage Cell Therapeutics' Payables stood at $4.6 million, which was up 163.06% from $4.5 million recorded in Q2 2025.
- Over the past 5 years, Lineage Cell Therapeutics' Payables peaked at $28.0 million during Q4 2021, and registered a low of $4.5 million during Q2 2025.
- Moreover, its 5-year median value for Payables was $5.4 million (2024), whereas its average is $7.2 million.
- In the last 5 years, Lineage Cell Therapeutics' Payables skyrocketed by 31052.4% in 2021 and then crashed by 6922.31% in 2022.
- Over the past 5 years, Lineage Cell Therapeutics' Payables (Quarter) stood at $28.0 million in 2021, then plummeted by 69.22% to $8.6 million in 2022, then decreased by 27.16% to $6.3 million in 2023, then decreased by 13.29% to $5.4 million in 2024, then dropped by 16.31% to $4.6 million in 2025.
- Its Payables was $4.6 million in Q3 2025, compared to $4.5 million in Q2 2025 and $5.0 million in Q1 2025.